Algeria holds approximately 30% of Africa’s total pharmaceutical manufacturing capacity. National production exceeded $4 billion in 2024, with nearly 80% of medicines marketed domestically now produced in-country. A first-in-Africa raw material production unit for anti-cancer drugs was launched in Sétif in 2024.
Annual Production · 2024
Domestic Medicines — Locally Produced
Africa’s First Anti-Cancer Raw Material Unit
Algeria has built approximately 30% of Africa’s total pharmaceutical manufacturing capacity without receiving anything close to commensurate international attention. The sector’s growth has been driven by a deliberate import substitution strategy — the government progressively restricted pharmaceutical imports while simultaneously building local manufacturing capacity, creating a captive domestic market that funded industrial scale. The result is a manufacturing base that is now large enough to look outward toward sub-Saharan export markets.
National pharmaceutical production exceeded $4 billion in 2024, with nearly 80% of medicines marketed domestically now produced in-country — a self-sufficiency level that most African countries will not achieve for decades. The sector is anchored by Saïdal Group, the state-owned pharmaceutical company, alongside over 200 private manufacturers. Major international companies including Sanofi, GSK, and Pfizer have local production or licensing arrangements in Algeria.
Algeria’s pharmaceutical sector is pivoting from import substitution — which it has substantially achieved — to active export ambition toward sub-Saharan Africa and MENA markets. For European pharmaceutical companies, this pivot creates a specific technology transfer and licensing window: Algeria has the manufacturing capacity, the regulatory framework, and the market access relationships; European companies have the proprietary formulations and the global distribution networks. The partnership argument is bilateral and commercially explicit.
The 2024 launch of a raw material production unit for anti-cancer drugs at Sétif — the first such facility on the African continent — signals the sector’s ambition to move upstream in the pharmaceutical value chain. Raw material production is significantly higher-margin than finished medicine manufacturing and creates genuine competitive differentiation in export markets. For global pharmaceutical companies evaluating African manufacturing partnership strategies, Algeria’s combination of scale, infrastructure, and policy support creates a credible industrial partnership opportunity.
Africa pharma share
~30% of total capacity
Annual production
$4BN+ · 2024
Domestic self-sufficiency
~80% locally produced
Private manufacturers
200+ in sector
Anti-cancer unit
Africa first — Sétif 2024
Saïdal Group
State anchor — listed company
International presence
Sanofi, GSK, Pfizer — active
Sub-Saharan export ambition — technology transfer and licensing window open now for European pharma companies.
Algeria.com — operational since the late 1990s. Five partnership pathways available.